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ABSTRACT
PSA-TRICOM is a therapeutic vaccine in late stage clinical testing in metastatic
castration-resistant prostate cancer (mCRPC). Samarium-153-ethylene diamine
tetramethylene phosphonate (Sm-153-EDTMP; Quadramet®), a radiopharmaceutical,
binds osteoblastic bone lesions and emits beta particles causing local tumor cell
destruction. Preclinically, Sm-153-EDTMP alters tumor cell phenotype facilitating
immune-mediated killing. This phase 2 multi-center trial randomized patients to
Sm-153-EDTMP alone or with PSA-TRICOM vaccine. Eligibility required mCRPC, bone
metastases, prior docetaxel and no visceral disease. The primary endpoint was
the proportion of patients without radiographic disease progression at 4 months.
Secondary endpoints included progression-free survival (PFS), overall survival (OS),
and immune responses. Forty-four patients enrolled. Eighteen and 21 patients were
evaluable for the primary endpoint in Sm-153-EDTMP alone and combination arms,
respectively. There was no statistical difference in the primary endpoint, with two of
18 (11.1%) and five of 21 (23.8%) in Sm-153-EDTMP alone and combination arms,
respectively, having stable disease at approximately the 4-month evaluation time
point (P = 0.27). Median PFS was 1.7 vs. 3.7 months in the Sm-153-EDTMP alone
and combination arms (P = 0.041, HR = 0.51, P = 0.046). No patient in the Sm-153EDTMP alone arm achieved prostate-specific antigen (PSA) decline > 30% compared
with four patients (of 21) in the combination arm, including three with PSA decline
> 50%. Toxicities were similar between arms and related to number of Sm-153EDTMP doses administered. These results provide the rationale for clinical evaluation
of new radiopharmaceuticals, such as Ra-223, in combination with PSA-TRICOM.
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INTRODUCTION

to induce immunogenic modulation, i.e., altering the
phenotype of tumor cells to render them more susceptible
to T-cell–mediated killing [23]. We thus sought to
determine if the use of the palliative Sm-153 EDTMP
radionuclide would enhance the therapeutic efficacy of the
PSA-TRICOM vaccine. The results reported here support
the hypothesis of vaccine radionuclide combination
therapy and provide the rationale for the clinical evaluation
of a therapeutic radionuclide conjugate such as Ra-223 in
combination with PSA-TRICOM vaccination.

Despite recent advances in the treatment of prostate
cancer, an estimated 27,540 men died of metastatic
disease in the U.S. in 2015 [1]. Approximately 90% of
patients with advanced metastatic castration-resistant
prostate cancer (mCRPC) have bone lesions, constituting
a significant disease burden responsible for morbidity and
mortality. Targeting of bone lesions through radionuclides
is a reasonable approach in widespread disease. Samarium153-ethylene diamine tetramethylene phosphonate
(Sm-153-EDTMP, Quadramet®) is a radiopharmaceutical,
which is preferentially absorbed by osteoblastic bone
lesions and emits beta particles that cause local tumor cell
destruction. It was approved by the United States Food
and Drug Administration based on improvement of pain
symptoms related to bone lesions [2, 3].
PSA-TRICOM
(PROSTVAC,
rilimogene
galvacirepvec/rilimogene glafolivec) is an active
immunotherapeutic cancer vaccine designed to induce
activation of T cells specific against prostate-specific
antigen (PSA) [4] and has an excellent safety profile
[5– 8] alone or with external beam radiotherapy [9, 10]. In
a randomized placebo-controlled phase 2 study in patients
(n = 125) with minimally symptomatic or asymptomatic
mCRPC, subjects randomized to PSA and a triad of
costimulatory molecules (PSA-TRICOM) vaccine had
a significantly prolonged median overall survival (OS)
compared with those who received empty vector placebo
(25.1 vs 16.6 months, hazard ratio (HR) 0.56, stratified
log-rank P = 0.0061) [8]. Based on those findings, a
multi-national phase 3 clinical trial (NCT 01322490) was
initiated and has now completed enrollment.
Despite the improvement in OS observed in the
randomized phase 2 trial of PSA-TRICOM, there was
no difference in progression-free survival (PFS) [8].
This has been observed in other clinical trials involving
immunotherapeutics [11, 12], and we have previously
hypothesized that a growth rate kinetics model may
explain this confounding finding [13–15]. Indeed, the
mechanism of action with therapeutic cancer vaccines
suggests that a delayed effect should be expected as
repeat vaccinations over months are likely to be required
to expand antigen-specific T cells, strengthen antigen
spreading, and effect an anti-tumor response. This
hypothesis has driven the design of phase 2 studies in
which we combine therapeutic cancer vaccines with
standard agents capable of controlling disease, allowing
more time for the generation of a broader, perhaps more
clinically relevant, immune response [16, 17].
Radiation has been implicated in immunogenic cell
death [18, 19] and immunogenic modulation [20, 21],
making it an excellent candidate for combination with
immunotherapy, including a randomized phase 3 trial
combining radiation therapy with ipilimumab [22]. Our
group demonstrated the capability of Sm-153-EDTMP
www.impactjournals.com/oncotarget

RESULTS
Patient baseline characteristics
Forty-four patients were enrolled between February
2007 and May 2012 at National Cancer Institute (n = 27),
University of Chicago (n = 9), and Rutgers Cancer Institute
of New Jersey (n = 8). Although the trial was designed to
enroll 68 patients, the study was ended early due to poor
accrual. Twenty-two patients were randomly assigned to
each arm. Four patients in arm A and one patient in arm
B were not evaluable (Figure 1). Baseline demographics
and known prognostic variables were similar between the
two groups (Table 1).

Safety
The majority of adverse events were attributable
to Sm-153-EDTMP. Grade 3 and 4 events were similar
between both arms when controlled for the number of doses
of Sm-153-EDTMP given in each arm (Supplementary
Table S1). Hematologic toxicities were most commonly
associated with Sm-153-EDTMP. The most common
adverse event attributed to vaccine was injection site
reaction, which was transient, self-limited, and did not
exceed grade 2 in all cases (34 events in 10 distinct patients).

Clinical outcomes
Of 44 patients enrolled, 18 and 21 were evaluable
for the primary endpoint in arms A and B, respectively
(Figure 1). There was no statistical difference in the
primary endpoint, with two of 18 (11.1%) in arm A
and five of 21 (23.8%) in arm B having stable disease
at approximately the 4-month evaluation time point
(P = 0.27). Based on the same 39 patients evaluated for
the 4-month endpoint, however, the median PFS was 1.7
and 3.7 months in arms A and B, respectively (P = 0.021,
one-tailed, P = 0.041, two-tailed, with HR = 0.51,
P = 0.046, 95% CI on HR: 0.26–0.99; Figure 2). If, in
addition, we include the other five patients who were
inevaluable for the 4-month PFS evaluation, resulting
in 44 total patients, the median PFS remains 1.7 and 3.7
months, but now with inevaluable patients, one-tailed
P = 0.025 and two-tailed P = 0.051, with HR = 0.52,
69015
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Table 1: Baseline characteristics
Characteristic

Sm-153 (A)
n = 22

Sm-153 + PROSTVAC (B)
n = 22

p-values*

8/22 (36%)
P = 0.22
Median (range)
Gleason score
8 (6–9)
7.5 (5–10)
P = 0.81
Age
64.5 (50–80)
69.2 (52–86)
P = 0.058
PSA on study
259.1 (22.2–1856)
313.5 (4.9–4708)
P = 0.78
ECOG performance status
1 (0–1)
1 (0–2)
P = 0.52^/P = 0.28#
Median days since prior chemotherapy
57.5 (11–301)
86.5 (21–818)
P = 0.30
Lactate dehydrogenase (serum)
254.5 (175–353)
200 (115–962)
P = 0.31
Hemoglobin
11.2 (8.8–13.2)
11.1 (7.0–14.8)
P = 0.80
Alkaline phosphatase
177 (90–725)
121.5 (52–661)
P = 0.041
ECOG, Eastern Cooperative Oncology Group, NCI; PSA, prostate-specific antigen.
*P-values determined by exact Wilcoxon rank sum test except where noted (^-Fisher’s exact test; # = Cochran-Armitage
test for trend).
Subjects requiring narcotic pain control

11/19 (58%)

Immune assays

two- tailed P = 0.056, 95% CI on HR: 0.27–1.02 (data
not shown). No PSA serum response was observed in arm
A. In arm B, four of 21 (19%) evaluable patients had PSA
decline ≥ 30% and three of 21 (14.3%) had PSA decline
≥ 50% (Table 2, Figure 3). No statistical difference in OS
was observed between the two arms, with a median of 8.1
and 9.2 months, respectively, in arms A and B (HR = 0.71,
95% CI on HR: 0.37–1.35 inevaluable 0.30).

Sufficient PBMCs were available pre- and posttherapy (approximately 60 days) from eight patients
treated with Sm-153-EDTMP alone and 10 patients
administered Sm-153-EDTMP plus vaccine to measure
PSA-specific CD4+ and CD8+ T-cell responses. The
FACS-based assay for T cells expressing type I cytokines

Figure 1: CONSORT diagram. The CONSORT diagram illustrates the patients enrolled, randomized, and evaluable for study endpoints.
www.impactjournals.com/oncotarget
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Table 2: Clinical outcomes
Evaluable patients
PFS
   Fraction at 4 months
   Median PFS months

Sm-153 (A)
n = 18

Sm-153 + PROSTVAC (B)
n = 21

Statistics for comparison

2/18 (11.1%)
1.7

5/21 (23.8%)
3.7

P = 0.27
P = 0.021 (one-tailed),
0.0412 (two-tailed)
HR 0.51, P = 0.046

Pt # confirmed PSA decline
   ≥ 30%
0
   ≥ 50%
0
PFS, progression-free survival; PSA, prostate-specific antigen.
IFN-γ, IL-2, TNF-α, and/or CD107a (a marker for lytic
potential) is described in detail in the Methods section.
Two of eight (25%) patients in the Sm-153-EDTMP
alone arm developed measurable PSA-specific responses
following therapy, while six of 10 (60%) in patients treated
with Sm-153-EDTMP plus vaccine developed PSAspecific T cells (P = 0.19 by Fisher’s exact test; Table 3).
Four out of 18 patients had some level of PSA-specific
T cells prior to therapy; of those, only one out of four went
on to develop enhanced PSA-specific T-cell responses
post–Sm-153-EDTMP plus vaccine therapy. CD107a
positivity is known to be a marker of a T cell with lytic
potential. One of eight patients in the Sm-153-EDTMP

4/21 (19.0%)
3/21 (14.3%)

alone arm developed CD107a+, CD4+ or CD8+ T cells
post-therapy, while five of 10 patients in the combination
arm developed CD107a+, CD4+ or CD8+ T cells posttherapy (P = 0.15; Table 3).
Sufficient PBMCs were available from a subset
of patients treated at the NCI that received Sm-153EDTMP alone (n = 7) or Sm-153-EDTMP plus vaccine
(n = 9) for the analysis of 110 different immune cell
subsets (Supplementary Table S2) at pre- and post-therapy
(~day 60). There were no significant changes in the nine
standard immune cell subsets evaluated, including CD4+
T lymphocytes, CD8+ T lymphocytes, regulatory T cells
(Tregs), natural killer (NK) cells, NK T cells, B lymphocytes,

Figure 2: Progression-free survival (PFS). Kaplan-Meier curve of PFS of patients on arm A (Sm-153-EDTMP alone) vs arm B
(Sm- 153-EDTMP in combination with PSA-TRICOM vaccine). Median PFS in arm B was 3.7 months compared with 1.7 months in arm
A, P value 0.021 (one-tailed), 0.041 (two-tailed).
www.impactjournals.com/oncotarget
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Table 3: Sm-153 ± PROSTVAC trial

Quadramet + PROSTVAC

Quadramet Alone

PSA-specific T-cell responses post- vs. pre-treatment
CD4
CD8
# of Responsesa
PT
CD107a IFN-γ
IL2
TNF
CD107a IFN-γ
IL2
TNF
11
0
0
0
0
0
0
56
186
13*
0
0
0
0
0
0
0
3
20*
0
0
0
0
0
0
0
0
1427
274
22
154
0
0
0
0
0
2/8 (25%)
630
25
146
0
0
0
0
248
30
3
0
0
0
0
0
0
14
0
5
0
0
0
0
0
0
0
25
10
0
6
0
0
0
21
0
0
786
0
374
5269
453
0
2
0
323
345
633
8
58
0
245
136
0
35
12
0
0
0
0
58
0
0
0
402
18
0
0
75
0
0
0
35
21
0
45
0
0
0
214
0
0
6/10 (60%)
1242
24*
0
0
149
181
0
8
179
821
14
0
0
0
0
0
0
0
0
16
0
0
0
0
0
9
0
815
26
0
0
0
149
0
0
0
27*
0
0
0
0
0
0
0
0
a
Cytokine or CD107a in CD4 or CD8.
*Patients displayed pre-existing PSA-specific T-cell responses.
Numbers in bold are those positive post- vs. pre-vaccination.
Absolute # of CD4 or CD8 producing cytokine or CD107a+/1 × 106 cells plated at start of in vitro stimulation.
conventional dendritic cells (DCs), plasmacytoid DCs,
or myeloid derived suppressor cells (MDSCs) pre- vs
post-therapy in patients in either arm (Supplementary
Table S3). Evaluation of 101 additional subsets relating
to the maturation/function of the nine standard immune
cells identified some trends (Supplementary Table S4).
Notably, patients receiving Sm-153-EDTMP alone, but not
Sm-153-EDTMP plus vaccine, displayed an increase in
several MDSC subsets, including those expressing PDL1
(PDL1 + MDSC, P = 0.016) that are reported to have a
suppressive function [24]. In contrast, patients treated with
Sm-153-EDTMP plus vaccine displayed trends mainly in T
lymphocytes in relation to memory and activation status not
seen with Sm-153-EDTMP alone. Both CD4 and CD8 cells
with an activated phenotype (ICOS+PDL1+CD4, P = 0.020,
and PDL1+CD8, P = 0.039) were decreased, while central
memory CD4 were increased (P = 0.020), which would be
expected to be immune potentiating.
Soluble CD40L in sera has been implicated as
a negative prognostic indicator in some cancers, and is
associated with decreased immune cell function. The
serum levels of sCD40L were measured before and during
therapy in both arms. There was no overall change in
www.impactjournals.com/oncotarget

patients receiving Sm-153-EDTMP alone (Figure 4A),
but a trend toward decreased sCD40L (P = 0.0046) in
patients receiving Sm-153-EDTMP in combination with
vaccine (Figure 4B), indicating a potential enhancement
in immune cell function by the vaccine.

DISCUSSION
The trial presented here was designed to evaluate
whether the addition of vaccine to Sm-153-EDTMP could
improve PFS at 4 months. Despite the poor accrual of
this trial due to newly available active oral agents in the
post-docetaxel setting which limited the interpretability of
the primary endpoint, we found a significant increase in
PFS. In addition to the improvement in PFS, we observed
evidence of serum PSA declines in the combination arm
that were not seen in the Sm-153-EDTMP alone arm.
It is important to put the PFS findings from this study
in the context of contemporary studies conducted in mCRPC
patients previously treated with docetaxel that accrued prior
to the approval of enzalutamide and abiraterone. For example,
the phase 3 trial that led to the approval of cabazitaxel
demonstrated a median PFS of 1.4 months for the control
69018
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Figure 3: Serum PSA Waterfall plot. Greatest percentage change in PSA for each patient while on treatment. (A) (Sm-153-EDTMP
alone, n = 18 evaluable.) No patient achieved a PSA decline of > 30%. (B) (Sm-153-EDTMP in combination with PSA-TRICOM vaccine,
n = 21 evaluable.) 4/21 patients achieved > 30% PSA decline and 3/21 achieved > 50% PSA decline.

Figure 4: Serum levels of sCD40L. Serum levels of sCD40L decreased significantly after treatment with Sm-153-EDTMP in

combination with vaccine. Soluble CD40L in serum was measured by ELISA before and during therapy. (A) Patients treated with Sm-153EDTMP alone. (B) Patients treated with Sm153-EDTMP and vaccine. Dot plots show results for individual patients, the median and the
interquartile range. Wilcoxon signed rank test. **P = 0.0046.
www.impactjournals.com/oncotarget
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(mitoxantone and prednisone) compared to 2.8 months in
median PFS for patients treated with cabazitaxel. Based on
these values, it would seem that the Sm-153-EDTMP control
group patients in this study (PFS 1.7 months) are similar to
other patients treated with palliative therapies at that time.
The resulting improvement in PFS compared to a control
group with median PFS similar to that of a historical control
is encouraging and requires further exploration.
Despite the inability to complete accrual of this
trial, which was likely attributable to the recent approval
of a number of new agents for mCRPC, we observed a
suggestion of clinical benefit with the combination of
Sm- 153-EDTMP and PSA-TRICOM compared with Sm153-EDTMP alone without the burden of additional toxicity.
These results support the hypothesis that therapeutic cancer
vaccines may slow tumor growth over time and treatment
with vaccines in combination with synergistic cytotoxic
agents may provide ample time and relative tumor control
to convey clinical benefit [17]. We believe this finding to be
consistent with the previous finding that vaccine alone does
not improve PFS but does improve OS [12] and supports
the growth rate kinetics model previously created based on
the clinical trial data using PSA-TRICOM alone [15].
A reasonable concern related to the use of
radiotherapeutic agents in combination with immunotherapy
is the potential to cause destruction of immune cell subsets
and prevent immune-mediated anti-tumor activity. However,
previous work from our group demonstrated no increase in
apoptosis of immune cells in the tumor microenvironment
of mice treated with vaccine and a radiolabeled monoclonal
antibody compared with vaccine alone [25], indicating
memory T cells are more resistant to radiation induced
apoptosis than naïve T cells, similar to the findings of other
groups [26]. The immune analyses reported here indicate that
Sm-153-EDTMP did not have a deleterious effect on any of
the 110 immune cell subsets in PBMCs in either arm, and
patients in the vaccine arm were still able to mount CD107a+
PSA-specific T cells, providing evidence of lytic potential.
Additionally, there was a trend toward increased number of
PSA-specific T cells generated in the combination arm and
a trend toward decreased sCD40L, despite the small number
of evaluable patients for these analyses. Careful selection of
the agent for use in combination is essential. We selected
Sm-153-EDTMP based on previous preclinical data, which
demonstrated the capacity of Sm-153-EDTMP to induce
“immunogenic modulation” in tumor cells, making them
more amenable to T-cell–mediated killing. The lack of PSA
responses with Sm-153-EDTMP alone compared with PSA
responses when used in combination (Table 2, Figure 3)
further suggests activity of the combination.

with pathology diagnosis confirmed by the Laboratory
of Pathology, National Institutes of Health. No visceral
metastases were allowed, but small, asymptomatic lymph
nodes were allowed. Previous treatment with docetaxel
was required, and there were no limits on the number of
prior chemotherapy or hormonal therapy regimens allowed
for enrollment. Prior treatment with Sm-153-EDTMP
was not allowed. Subjects were required to remain
on testosterone-suppressing therapy unless they were
surgically rendered castrate. Subjects were required to be
≥ 18 years of age, have acceptable hematologic parameters
and organ function, have an Eastern Cooperative Oncology
Group (ECOG) performance status of ≤ 2, have no other
malignancies within 12 months, or significant medical
illnesses or autoimmune diseases. No systemic steroid
use was allowed within 2 weeks of enrollment. Due to
vaccinia vector used in priming, subjects with a history
of prior allergy or severe reaction to vaccinia-based
vaccination or an open skin wound were also excluded.
This study is registered with ClinicalTrials.gov, number
NCT00450619.

MATERIALS AND METHODS

Statistical considerations

Patient eligibility

This was conducted as a randomized two-arm trial,
with the primary endpoint being a comparison of the
proportion of patients on each arm with progression at
a 4-month evaluation. The study was designed to enroll

Trial design and treatment
Subjects were randomized 1:1 to receive
Sm- 153-EDTMP alone (arm A) or in combination with
PSA-TRICOM (arm B). All subjects were treated with
Sm- 153-EDTMP per standard dosing, 1 mCi/Kg IV over
1 minute, which was given on day 8 after randomization
(to allow for ordering radionuclide) and then every
12 weeks if adequate hematologic recovery had occurred.
In arm B, subjects also received subcutaneous injections
of rV-PSA-TRICOM on day 1 (2 × 108 plaque-forming
units (PFU)) and then rF-PSA-TRICOM (1 × 109 PFU)
on days 15 and 29, and every 28 days thereafter. Baseline
imaging, consisting of bone scan and CT chest/abdomen/
pelvis, was performed prior to randomization and repeated
at 2 months, 4 months, and then every 3 months thereafter.
To account for scintigraphic “flare” phenomenon
described with effective treatment [28], the repeat bone
scan at 2 months was used as the baseline if any changes
occurred and for comparison to the 4-month restaging
scan. Disease progression was defined using ProstateSpecific Antigen Working Group criteria [29]. Adverse
events were monitored using Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0. The
treatment protocol was approved by the National Cancer
Institute, University of Chicago, and Rutgers Cancer
Institute of New Jersey, Institutional Review Boards and
subjects were enrolled at each institution.

Subjects were required to have mCRPC with
bone metastases as determined by CT and/or bone scan
www.impactjournals.com/oncotarget
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34 evaluable patients per arm (68 total) to provide 80%
power to detect a difference between 15% and 40% PFS at
4 months in arms A and B, respectively, using a one-tailed
alpha = 0.10 Fisher’s exact test, following the principles
of a phase 2.5 study design [30]. Secondary endpoints
included an overall analysis of PFS, OS, and changes in
serum PSA, comparison of toxicity, and evaluation of
antigen-specific T-cell activation. Analyses of PFS were
performed using the Kaplan-Meier method, beginning
at the on-study date through the date of progression or
last follow-up without progression. The hazard ratio
(HR) comparing the two curves was estimated using Cox
regression analysis. Comparisons of pre-treatment and
post-treatment immune parameters were performed with
a Wilcoxon signed rank test. Except as noted, all P values
are two-tailed, and all are presented without adjustment
for multiple comparisons.
Baseline characteristics using all available data
from the 22 patients randomized per arm were compared
between the two arms using an exact form of the Wilcoxon
rank sum test for continuous parameters. The fraction of
patients requiring narcotics, as well as the fraction of
patients with ECOG performance status 0 vs. 1–2, were
compared between the two arms using Fisher’s exact
test. The actual distribution of ECOG performance status
values was also compared between the arms using a
Cochran-Armitage test for trend.

to the maturation/function of the standard subsets
(Supplementary Table S4). For all flow cytometry
experiments, upto 3 × 105 live events were acquired with
a BD LSR-II flow cytometer. Data were analyzed with
FlowJo V.9.7 for Macintosh (TreeStar, Ashland, OR) with
fluorescence minus one controls used for gating, and nonviable cells excluded.
Antigen-specific responses were assessed by
intracellular cytokine staining (ICS) following a period
of in vitro stimulation (IVS) of PBMCs with overlapping
15-mer peptide pools encoding the tumor-associated
antigen (TAA) PSA. The PSA peptide pool contained a
previously identified agonist epitope [31]; pools encoding
for HLA and CEFT (a mixture of CMV, EBV, Flu, and
tetanus toxin) served as negative and positive controls,
respectively. PBMCs from patients before and 60 days
following therapy were stimulated in an IVS and stained
with antibodies (listed in Supplementary Table S6)
to identify the absolute number of CD4+ or CD8+
lymphocytes producing cytokine (IFN-γ, TNF, or IL-2)
or positive for CD107a as previously described [32]. The
background signal (obtained with the HLA peptide pool)
and values obtained prior to therapy were subtracted from
those obtained post-therapy. Values >250 were scored as
positive for TAA-specific immune response following
therapy if they were also at least 2-fold greater than that
obtained with HLA.
The serum levels of sCD40L were determined by
the human sCD40L Platinum ELISA kit (eBioscience, San
Diego, CA) according to the manufacturer’s instructions
and as previously described [33].

Randomization and masking
Patients were randomized centrally, without
stratification, using a locally-written SAS software
program to generate a random 1:1 sequence of assignments
to treatment, using variable block sizes (2 or 4), with
parameters for assignment determined by the study
statistician (SMS). The randomization assignment sheets
were maintained confidentially in a central registration
office, which enrolls the patients; the treatment assignment
for a given patient was only disclosed to the study research
team by a member of the central registration staff after
confirming full eligibility.

CONCLUSIONS
Sm-153-EDTMP in combination with PSATRICOM appears to lead to clinically meaningful
improvement in PFS and is associated with trends
to improved PSA declines and PSA-specific T-cell
responses compared with Sm-153-EDTMP alone. This
study has limitations due to the small number of patients
enrolled, but it did achieve the goal of providing the
rationale for and estimates for statistical assumptions
for a larger, randomized study employing a modern
radiopharmaceutical in combination with PSA-TRICOM.
Ra-223, one such modern radiopharmaceutical that was
more recently approved for the treatment of mCRPC,
may be a better selection for use in combination
with immunotherapy, due to its demonstrated effect
on overall survival [27], compared with Sm-153EDTMP, which has greater hematologic toxicity and
only demonstrated a palliative effect in clinical trials.
Ongoing preclinical testing will determine if Ra-223
has similar immunomodulatory effects to support its use
in combination with immunotherapy in future clinical
trials.

Immune assays
Peripheral blood mononuclear cells (PBMCs) were
isolated, cryopreserved, and assessed for the frequency of
immune cell subsets by multi-parametric flow cytometry
as previously described [17]. One vial of PBMCs from
patients before therapy (baseline) and at approximately
day 60 of therapy was defrosted and stained in panels
using antibodies (listed in Supplementary Table S5) to
identify nine standard immune cell subsets including
CD4+ and CD8+ T lymphocytes, Tregs, NK cells, NK-T
cells, B lymphocytes, conventional and plasmacytoid
DCs, and MDSCs, and 101 additional subsets relating
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